BIOMORGAN LIMITED

Booth No: N1108

Exhibitor Profile

BiomOrgan is a Hong Kong-based life science company founded in 2021 at the Hong Kong Science and Technology Parks. A spin-off from the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT), HKU. It is the first company in the Asia-Pacific region to develop and commercialize a leading respiratory organoid platform. BiomOrgan supports academic, pharmaceutical, and biotech partners in accelerating biomedical research, disease modelling, drug screening, and therapeutic development.

Brands

Video

Exhibit Products

Booth Events

Asia’s First Integrated Organoid‑Based Precision Medicine Centre Driving Translational Impact

Cancer treatment still follows one‑size‑fits‑all guidelines, even though tumours vary widely in behaviour and drug response. Many patients lack actionable mutations, leaving clinicians without reliable guidance. Patient‑derived organoids (PDOs) grow a patient’s tumour into “mini‑tumours” for testing therapies in the lab, offering functional, patient‑specific insight to support more informed treatment decisions.

Event Time and Details

The 1st Human Respiratory Organoid Culture System: Transforming Respiratory Vaccines and Therapeutic

Limitations of outdated animal and cell‑line models hinder drug and vaccine development, driving high clinical failure rates. There is growing demand for human‑relevant, scalable models, especially for validating AI‑generated drug candidates. Our human respiratory organoid platform—“mini lung in a dish”—offers superior, clinically predictive models and enables cultivation of previously uncultivable viruses.